secwatch.observer — SEC 8-K summary
======================================

Issuer:     Wave Life Sciences Ltd. (WVE)
CIK:        0001631574
Form:       8-K
Filed at:   2025-10-29T23:59:59+00:00
Accession:  0001193125-25-256682
Event type: other_material
Sentiment:  positive
Materiality: 0.65
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Wave Life Sciences reports positive target engagement data for WVE-007 in obesity; Activin E reductions up to 85%
--------------------------------------------------------------------------------

- WVE-007 achieved Activin E reductions of 85% (400mg), 75% (240mg), 56% (75mg) at one month, all highly significant (p<0.0001).
- 75mg cohort showed durable reduction through 6 months, supporting once or twice yearly dosing.
- WVE-007 safe and well tolerated; independent data monitoring committee supported dose expansion and escalation.
- Multiple clinical data updates including body composition and weight expected starting 4Q2025.
- Announced WVE-008 RNA editing candidate for PNPLA3 liver disease; CTA filing anticipated in 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1631574/000119312525256682/0001193125-25-256682-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1631574/000119312525256682/d95356d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-256682

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer